
Well Appearing Febrile Infant





| Created by | Department | Creation Date | Version Date |
|-------------|------------|---------------|--------------|
| H. Greening | Pediatrics | Jan 2023 | July 2024 |
| | | | |

Well Appearing Febrile Infant



Definition of Abnormal Laboratory Parameters:

- Urinalysis (collected via catheter or suprapubic aspirate)
 - > 5 WBCs/hpfOR
 - Presence of leukocyte esterase
- Inflammatory Markers
 - Procalcitonin > 0.5 ng/mLOR
 - o ANC > 4,000 cells/mm³
- CSF Pleocytosis
 - 0-28 days old > 18 WBC/mm³
 - \circ 29-60 days old > 9 WBC/mm³

²Labs for LP:

- CSF cell count, protein, glucose
- CSF culture
- If pleocytosis, add meningitis/encephalitis panel to standard CSF studies

HSV risk assessment

- Maternal vesicles within 48 hours before or after delivery
- Seizure
- Skin vesicles
- Mucous membrane ulcers
- Elevated AST or ALT
- Thrombocytopenia
- Hypoglycemia
- CSF pleocytosis
- Leukopenia
- Hypothermia

HSV Evaluation/Treatment

- HSV PCR [HSVPCR], source: blood
- HSV surface swabs [NEOHS]; using one order, collect separate swabs from eyes, nose, mouth, rectum, and skin lesion (if present)
- Meningitis/encephalitis panel [RMEPNL]
- Acyclovir (IV)

If risk factor

present,

proceed

| Anti | imicrobial | Age (days) | Dose (mg/kg/dose) | Route | Interval |
|--------------------------|-----------------|------------|-------------------|-------|----------|
| Acyclovir | | 0-60 | 20 | IV | Q8h |
| Ampicillin | Standard dose | 0-21 | 50 | IV | Q8h |
| | Meningitis dose | 0-7 | 100 | IV | Q8h |
| | | 8-21 | 75 | IV | Q6h |
| Cefotaxime | Cefotaxime | | 50 | IV | Q8h |
| Ceftriaxone ^β | Standard dose | 22-60 | 50 | IV | Q24h |
| Certriaxone | Meningitis dose | 22-60 | 50 | IV | Q12h |
| Cephalexin | | 29-60 | 25 | PO | Q8h |
| Contonicio | | 0-7 | 4 | IV | Q24h |
| Gentamicin | 8-21 5 | | 5 | IV | Q24h |

 eta Use ceftriaxone with caution/consider alternative agent in patients with total serum bilirubin > 5 mg/dL or receiving

Reference: Pantell RH, Roberts KB, Adams WG, et al. Clinical Practice Guideline: Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old. *Pediatrics*. 2021; 148(2):e2021052228

| Created by | Department | Creation Date | Version Date |
|-------------|------------|---------------|--------------|
| H. Greening | Pediatrics | Jan 2023 | July 2024 |
| | | | |

calcium containing IV products. Do not administer ceftriaxone and calcium simultaneously in same line